HIVE Digital closes $115M exchangeable notes offering at 0% rate

HIVE Digital closed a $115 million private offering of 0% exchangeable senior notes due 2031, with an initial exchange price of about $2.57 per share and an additional $15 million option fully exercised. Net proceeds are expected to be roughly $109.5 million, which will fund GPU purchases, data center development, and general corporate purposes, while the company also entered capped call transactions with a $4.92 cap price. The financing improves liquidity for growth initiatives, but the company is still loss-making with negative $138 million levered free cash flow over the last 12 months.

Analysis

This financing is less about balance-sheet relief and more about buying time for a capital-intensive pivot. The 0% coupon removes near-term cash interest drag, but the exchangeable structure effectively caps dilution only if the stock can sustain a materially higher level; otherwise, equity holders are underwriting an expensive quasi-equity layer with downside protection for note buyers and upside asymmetry for existing shareholders. The capped call partially neutralizes dilution, but only in the zone where the market would otherwise re-rate the stock hardest, which means the structure is most protective exactly when the equity is trying to rerate.

The key second-order effect is on peers and suppliers: if HIVE uses proceeds to add GPU capacity, it signals that incremental growth in AI/HPC is still being funded despite weak levered cash flow, which can keep demand tight for power, racks, and equipment even as mining economics stay volatile. That supports select infrastructure beneficiaries, but it also raises the bar for mining pure plays because capital markets are still open for issuers with narrative momentum, making relative valuation the more important signal than absolute fundamentals over the next 1-2 quarters.

The contrarian read is that the market may be overestimating the cash runway improvement from this raise. With negative free cash flow and a volatile equity, the financing likely postpones rather than resolves equity issuance risk; if operating momentum stalls or crypto prices fade, this could become a bridge to another raise before year-end. The relevant catalyst window is 30-90 days: if HIVE can show that AI/data-center investment translates into EBITDA conversion, the stock can squeeze toward the exchange price; if not, the deal simply monetizes optionality for the new noteholders and increases the probability of a lower-quality recap later.

Key Decisions for Investors

• Avoid chasing HIVE common into the financing close; use any post-deal strength into the exchange price area (~$2.57 equivalent) to fade upside, with a 1-3 month horizon and a tight stop above the capped-call zone logic.
• For event-driven risk, buy short-dated HIVE puts or put spreads if the stock rallies on headline deal completion; the asymmetric risk is another financing or guidance reset within 1-2 quarters, while downside can re-open quickly if growth conversion disappoints.
• Relative-value idea: long a profitable AI infrastructure beneficiary versus short HIVE over 2-6 months. The cleaner expression is long a data-center/power winner with positive FCF and short HIVE, because the market is likely to keep rewarding self-funded growth over capital-dependent growth.
• If you want exposure to the AI capex theme, prefer suppliers to HIVE over HIVE itself; the financing supports more spend on GPUs/data centers, but the equity is still burdened by dilution risk and weak cash generation.
• Speculative long only on a confirmed inflection: wait for a quarter showing positive operating cash flow or materially improved EBITDA conversion before owning HIVE outright. Until then, the risk/reward favors trading it as a financing story, not a fundamentals compounder.